Teva Pharmaceuticals slammed with €462.6m fine for blocking Copaxone competitors
Teva Pharmaceuticals, the generics powerhouse, has been slapped with a hefty fine of €462.6 million by the European Commission for anti-competitive practices related to its blockbuster multiple sclerosis drug, Copaxone. The fine marks one of the largest penalties imposed on a pharmaceutical company for breaching antitrust regulations in recent years, surpassing the penalty imposed on […]